ELVN-001 for the Treatment of Chronic Myeloid Leukemia With and Without T315I Mutation in Japanese Participants

The purpose of this study is to evaluate the safety, tolerability and determine the recommended dose for further clinical evaluation of ELVN-001 in Japanese patients with chronic phase chronic myeloid leukemia with and without T315I mutations in patients who has failed, or the patient is intolerant to, or not a candidate for, at least 2 prior TKIs.

Trial Details

NCT ID
NCT06787144
Phase
PHASE1
Sponsor
Enliven Therapeutics
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • ELVN-001
Locations (sample)
  • Akita, Akita, Japan|39.71667,140.11667
  • Sapporo, Hokkaido, Japan|43.06667,141.35
  • Suita-shi, Osaka, Japan
  • Shinjuku-ku, Tokyo, Japan

Key Eligibility Criteria

  • BCR::ABL1 positive CP-CML that has failed, or the patient is intolerant to, or not a candidate for, at least 2 prior TKIs.
  • ECOG performance status of 0 to 2.
  • The patient was born in Japan and both parents and grandparents are Japanese.
  • Adequate hematologic, hepatic and renal function.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →